IAM Advisory LLC Acquires Shares of 10,375 Gilead Sciences, Inc. $GILD

IAM Advisory LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,375 shares of the biopharmaceutical company’s stock, valued at approximately $1,273,000.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares in the last quarter. Wealthspire Advisors LLC raised its position in Gilead Sciences by 19.5% during the second quarter. Wealthspire Advisors LLC now owns 2,681 shares of the biopharmaceutical company’s stock worth $297,000 after acquiring an additional 437 shares during the period. Finally, Traub Capital Management LLC purchased a new position in Gilead Sciences during the second quarter valued at $54,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider owned 131,779 shares of the company’s stock, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 309,280 shares of company stock valued at $44,068,850 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Barclays started coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price on the stock. TD Cowen raised their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Scotiabank lifted their price objective on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. UBS Group boosted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Stock Down 2.8%

GILD stock opened at $137.21 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a 50-day moving average of $142.69 and a two-hundred day moving average of $127.77. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a market cap of $170.34 billion, a price-to-earnings ratio of 20.27, a PEG ratio of 1.85 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.